Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A prospective study of cancer risk among Agricultural Health Study farm spouses associated with personal use of organochlorine insecticides

  • Lydia M. Louis1, 2Email authorView ORCID ID profile,
  • Catherine C. Lerro1,
  • Melissa C. Friesen1,
  • Gabriella Andreotti1,
  • Stella Koutros1,
  • Dale P. Sandler3,
  • Aaron Blair1,
  • Mark G. Robson4 and
  • Laura E. Beane Freeman1
Environmental Health201716:95

https://doi.org/10.1186/s12940-017-0298-1

Received: 20 March 2017

Accepted: 14 August 2017

Published: 6 September 2017

Abstract

Background

Organochlorine insecticides (OCs) have historically been used worldwide to control insects, although most have now been banned in developed countries. Evidence for an association between OC exposures and cancer predominantly comes from occupational and population based-studies among men. We evaluated the association between the use of specific OCs and cancer among the female spouses of pesticide applicators in the Agricultural Health Study.

Methods

At enrollment (1993–1997), spouses of private applicators in the cohort provided information about their own use of pesticides, including seven OCs (aldrin, chlordane, dieldrin, DDT, heptachlor, lindane, and toxaphene), and information on potential confounders. We used Poisson regression to estimate relative risks (RRs) and 95% confidence intervals (CIs) for cancers (n ≥ 3 exposed cases) reported to state cancer registries from enrollment through 2012 (North Carolina) and 2013 (Iowa), and use of the individual OCs, as well as use of any of the specific OCs.

Results

Among 28,909 female spouses, 2191 (7.58%) reported ever use of at least one OC, of whom 287 were diagnosed with cancer. Most cancers were not associated with OC use. Risk of glioma was increased among users of at least one OC (Nexposed = 11, RR = 3.52, 95% CI 1.72–7.21) and specifically among lindane users (Nexposed = 3, RR = 4.45, 95% CI 1.36–14.55). Multiple myeloma was associated with chlordane (Nexposed = 6, RR = 2.71, 95% CI 1.12–6.55). Based on 3 exposed cases each, there were also positive associations between pancreatic cancer and lindane, and ER-PR- breast cancer and dieldrin. No other associations with breast cancer were found.

Conclusions

Overall, there were some associations with OC use and cancer incidence, however we were limited by the small number of exposed cancer cases. Future research should attempt to expand on these findings by assessing environmental sources of OC exposures, to fully evaluate the role of OC exposures on cancer risk in women.

Keywords

Agricultural Health Study Cancer Farm spouses Organochlorine Pesticide

Background

Organochlorine insecticides (OCs) are a class of chlorinated hydrocarbon insecticides historically used worldwide in agriculture. Some are still used in some developing countries for the control of vector borne illnesses [13]. OCs were first introduced in the United States in the 1940s and were used widely in agriculture and pest control through the 1960s. Due to their environmental persistence and ability to bioacccumulate, most OCs were banned for use in the U.S. during the 1970s and 1980s. Lindane and endosulfan were banned more recently in 2006 and 2010, respectively [46]. The International Agency for Research on Cancer (IARC) has reviewed the carcinogenicity of fifteen OCs. Of these, lindane [7] and pentachlorophenol (PCP) [8] were classified as Group 1, carcinogenic to humans; dichlorodiphenyltrichloroethane (DDT) [7], aldrin [8] and dieldrin [8] as Group 2A, probably carcinogenic to humans; 2,4,6-trichlorophenol (TCP) [8], chlordane [9], chlordecone [10], heptachlor [9], hexachlorocylcohexanes (HCH) [10], hexachlorobenzene (HCB) [9], mirex [10], and toxaphene [9] as Group 2B, possibly carcinogenic to humans; and endrin [10] and methoxychlor [10] classified as Group 3, not classifiable as to their carcinogenicity to humans.

The strongest epidemiologic evidence for a link between OC exposures and cancer risk comes from occupational and population-based studies of non-Hodgkin lymphoma (NHL) [1119]. Previous analyses of licensed pesticide applicators in the Agricultural Health Study (AHS) found significant positive exposure-response trends for lindane and DDT use with NHL [12], and chlordane and heptachlor use with leukemia [20]. In a pooled analysis of Canadian and U.S. based case–control studies, self-reported ever use of DDT was significantly associated with multiple myeloma (MM) [17]. The strongest evidence for associations with cancer at other sites comes from case–control studies of liver and testicular cancers [2124]. DDT, dichlorodiphenyldichloroethylene (ρ, ρ’ -DDE), and β-HCH have been associated with hepatocellular carcinoma [2123], and testicular germ cell tumors have been significantly associated with prediagnostic serum DDE and chlordane metabolites [24]. There is also evidence for significant positive associations with OC exposures and cancers of the prostate [25], skin (cutaneous melanoma) [20], lung [20], rectum [20], and pancreas [26, 27]. An evaluation of pesticides and glioma reported no association with OCs [28].

In addition, potential associations between OCs and hormonally-mediated cancers, particularly female breast cancer, are of concern due to the endocrine disrupting properties of OCs [2938]. While two studies [34, 35] have suggested an association with dieldrin, most studies are null [29, 32, 33, 3639]. However, several reports provide evidence for an increased risk of breast cancer in adulthood with early life exposure to OCs [4043]. The one study of endometrial cancer found no associations with OCs overall [44]. No studies to our knowledge have investigated associations with ovarian cancer. Although in vitro and in vivo studies suggest OCs may act as estrogen agonists or antagonists [4548], the relationship between OCs and hormonally-mediated cancers among women remains unclear. In this paper, we examine the associations between multiple site-specific cancers and self-reported personal use of OCs among the female spouses of AHS applicators.

Methods

Study population and follow-up

The AHS is a prospective cohort that includes licensed private pesticide applicators (mostly farmers), and the spouses of private pesticide applicators residing in Iowa and North Carolina. The AHS has been previously described in detail [49]. Pesticide applicators were recruited from 1993 to 1997 when obtaining a license to apply restricted-use pesticides. Private pesticide applicators who reported being married at the time of enrollment were given questionnaires to be completed by their spouses. The spouses (n = 32,345) of these private pesticide applicators are the focus of this study. The Spouse Enrollment questionnaire elicited information on demographic and lifestyle factors, family and personal medical histories, farm exposures, and agricultural activities, including the application or mixing of specific pesticides. In addition, 60.0% of the spouses in this analysis also completed the Female and Family Health questionnaire which focused on reproductive health histories. The study protocol was approved by all relevant institutional review boards. Study questionnaires are publicly available (https://aghealth.nih.gov/collaboration/questionnaires.html).

Cancer incidence was assessed regularly via linkage with the North Carolina and Iowa state cancer registries. Mortality incidence was assessed through regular linkage with state mortality registries and The National Death Index. Cancer sites were classified according to the International Classification of Diseases for Oncology, 3rd revision (World Health Organization). For NHL, we followed the Surveillance Epidemiology and End Results (SEER) lymphoma coding scheme [50].

Exposure assessment and questionnaires

Spouses of private pesticide applicators were enrolled in the AHS from 1993 to 1997, during which time they reported their lifetime never/ever personal use of fifty pesticides including past use of seven OCs (aldrin, chlordane, dieldrin, DDT, heptachlor, lindane and toxaphene). For each pesticide, they were asked ‘During your lifetime, have you ever personally mixed or applied [pesticide]? (Includes pesticides used for farm use, commercial application and personal use in your home or garden)’. Participants who indicated ever use of at least one of these seven OCs were classified as having personally used ‘any OC’, whereas those who indicated never use of any of these OCs were classified as never having personally used ‘any OC’. Otherwise, participants were considered to be missing as to their ‘any OC’ use. In the following analysis, the term ‘any OC’ will be used to refer to the ever personal use of at least one of these seven OCs.

Statistical analysis

For this analysis we excluded, the 219 male spouses, women who were diagnosed with cancer prior to study enrollment (n = 905), those with zero or missing person years of follow-up (n = 161), and those missing information on use for all seven OCs (n = 2146), leaving 28,909 female spouses in our analytic cohort. Relative risks (RR) and 95% confidence intervals (95% CI) were calculated for risk of cancer among ever users, compared to never users, using multivariable Poisson regression in SAS version 9.3 (SAS Institute, Inc., Cary, N.C.). We evaluated all cancer sites with at least three exposed cases for associations with each of the seven individual OCs and for the use of any OC as defined previously. Person-time accrued from the date of study enrollment until date of death, cancer diagnosis, movement out of state or last study-follow-up (December 31, 2012 and December 31, 2013 for North Carolina and Iowa respectively), whichever was earliest. For the evaluation of uterine and ovarian cancers, person-time was censored at the time of hysterectomy or oophorectomy, where applicable.

All models were adjusted for age at enrollment (≤44 years, 45–54 years, 55–64 years, ≥ 65 years), educational attainment (high school degree or less, some college or college graduate, one or more years of graduate school), alcohol use (never, less than 1 drink per month, ≥ 1–3 per month), cigarette pack-years smoked as reported at enrollment (pack-year quartiles: Never, ≤ 6.75, 6.751–16.75, ≥ 16.751), and state of residence (Iowa or North Carolina). We considered the following additional confounders: BMI, race, family history of cancer, and ever use of any pesticide, but did not include them in our final models as they did not appreciably alter our results by ≥ 10%. For all cancer sites, mutually adjusting for individual non-OC and OC pesticides that were correlated at ρ ≥ 0.4 (i.e. aldrin and dieldrin (ρ = 0.43), aldrin and heptachlor (ρ = 0.42)) did not appreciably change our results and these adjustments were not included in our final models. Moreover, because dieldrin is also a biological metabolite of aldrin, we performed sensitivity analyses where ‘dieldrin metabolite’ (i.e. those farm spouses who personally used either aldrin or dieldrin) was modeled as the exposure. However, these analyses did not significantly alter our existing aldrin and dieldrin results, and were not included in our final analyses.

Additionally, we examined potential confounders known to be associated with specific cancer sites, such as total meat consumption (colon, rectum, stomach), sun sensitivity (melanoma), asbestos exposure (lung), autoimmune disorders, exposure to livestock and poultry, and benzene exposure (lymphohematopoeitic cancers); adjusting for these specific cancer-related covariates did not alter our results and were not included in our final models. All OC-exposed brain cancer cases were glioma subtypes; thus, we report associations here for glioma only. Breast cancers were examined overall, as well as by estrogen receptor (ER) and progesterone receptor (PR) status, where available. Female health and reproductive covariates at enrollment were also examined, with respect to breast, ovarian and uterine cancer, and included the following: menopausal status, ever use of oral contraceptives, ever use of estrogen-based hormone replacement therapy, ever use of progestin based hormone replacement therapy, age at menarche, and parity. These female reproductive covariates did not appear to significantly alter our results and thus were not included in our final models. Due to a lack of questionnaire information availability, we were unable to assess age at first live birth as a potential covariate. We conducted stratified analyses by several female health covariates, including menopausal status at enrollment (yes/no), ever use of oral contraceptives at enrollment (yes/no), ever use of hormone replacement therapy at enrollment (yes/no) and age at first menarche (≤ 12 years or below, > 12 years). Due to the small number of nulliparous women (n = 294), we were unable to evaluate risks among nulliparous women.

Results

From enrollment through 2012/2013, the 28,909 female spouses contributed a total of 502,895 person-years of follow-up (Mean = 16.19 standard deviation +/− 3.8). Overall, 15,112 (52.3%) reported ever using any pesticide (data not shown), and 2191 (7.6%) reported ever use of any of the seven OCs included in the enrollment questionnaire. The most commonly reported OCs were chlordane (4.1%), DDT (3.55%) and lindane (1.5%), with less than 1% of participants reporting ever use of aldrin, heptachlor, toxaphene and dieldrin (Table 1). Among women who reported using any OC, 718 (32.8%) reported use of more than one OC. Ever OC users tended to be older, have higher BMIs, be from Iowa, and have a higher educational level than OC non-users. They were also more likely to have reported a family history of cancer, grown up on a farm, used oral contraceptives, and have an earlier onset of menarche. Additionally, 77.5% of OC users completed the Female and Family Health Questionnaire versus 60.5% of never OC users.
Table 1

Select characteristics of AHS farm spouses at enrollment with OC insecticide personal use information (n = 28,909)a

 

Any OC useb

 

Never

Ever

 

N = 26,718

%

N = 2,191

%

p value±

Age at enrollment

 ≤ 44

13,153

49.23

447

20.40

< .0001

 45–54

6,677

24.99

771

35.19

 

 55–64

4,823

18.05

731

33.36

 

 ≥ 65

2,065

7.73

242

11.05

 

Race

 White

26,164

97.93

2,178

99.4

< .0001

 Other

510

1.91

8

0.37

 

 Missing

44

0.16

5

0.23

 

State of Residence

 North Carolina

8,739

32.71

632

28.85

0.0002

 Iowa

17,979

67.29

1,559

71.15

 

Educational Attainment

 High School or less

13,905

52.04

1,102

50.3

0.0015

 Some College or College Graduate

8,662

32.42

679

30.99

 

 1 or more years of Graduate School

3,833

14.35

378

17.25

 

 Missing

318

1.19

32

1.46

 

Body Mass Index

 0–24.99

11,756

40.67

902

41.17

< .0001

 25.00–29.99

7,448

25.76

717

32.72

 

 ≥ 30.00

4,298

14.87

440

20.08

 

 Missing

3,216

11.12

132

6.02

 

Alcohol

 Never

12,042

45.07

939

42.86

0.2371

 Less than once/month

7,099

26.57

603

27.52

 

 ≥ 1–3 times per month

7,277

27.24

621

28.34

 

 Missing

300

1.12

28

1.28

 

Cigarette Smoking (Pack-years)

 Never Smoker

18,820

70.44

1,493

68.14

0.0003

 ≤ 6.75

3,544

13.26

294

13.42

 

 6.751–16.75

1,752

6.56

127

5.80

 

 ≥ 16.751

1,700

6.36

186

8.49

 

 Missing

902

3.38

91

4.15

 

Family History of Cancer

 No/Missing

13,949

52.21

949

43.31

< .0001

 Yes

12,769

47.79

1,242

56.69

 

Grew up on a farm

 No

10,913

40.85

534

24.37

< .0001

 Yes

15,579

58.30

1,643

74.99

 

 Missingc

226

0.85

14

0.64

 

Menopause at Enrollment

 No

8,922

33.39

534

24.37

< .0001

 Yes

6,777

25.36

1,127

51.44

 

 Unsure

245

0.92

22

1.00

 

 Missingc

10,774

40.32

508

23.19

 

Number of Live Births

 0

235

0.88

29

1.32

< .0001

 1 or 2

7,216

27.01

688

31.40

 

 > 2

7,526

28.17

887

40.48

 

 Missingc

11,741

43.94

587

26.79

 

Oral Contraceptive Use

 Never

4,236

15.85

576

26.29

< .0001

 Ever

11,722

43.87

1,106

50.48

 

 Missingc

10,760

40.27

509

23.23

 

Age of first menarche

 12 years or less

7,099

26.57

788

35.97

< .0001

 13 years

4,851

18.16

493

22.5

 

 14 years or greater

3,855

14.43

398

18.17

 

 Missingc

10,913

40.85

512

23.37

 

OC Insecticides

 Overall OC (Any OC)

-

-

2,191

7.58

-

 Chlordane

-

-

1,196

4.13

-

 DDT

-

-

1,028

3.55

-

 Lindane

-

-

430

1.47

-

 Aldrin

-

-

235

0.81

-

 Hepatchlor

-

-

222

0.77

-

 Toxaphene

-

-

203

0.70

-

 Dieldrin

-

-

105

0.36

-

AHS Agricultural Health Study, RR relative risks, OC organochlorines

±Chi Square test for homogeneity

aExcluded: n = 2146 with missing information for personal use of all OCs; n = 905 female spouses diagnosed with cancer prior to enrollment; n = 219 male spouses; n = 161 with missing or 0 person-years of follow-up leaving a total n = 28,909 female farm spouses

bEver use of any of the seven OC insecticides

cFrom Female & Family Health Questionnaire responses

Any OC use was significantly associated with an increased risk of glioma (Nexposed = 11; RR = 3.52, 95% CI 1.72 to 7.21) (Table 2). Lindane use was significantly associated with an increased risk of glioma (Nexposed = 3, RR = 4.45 95% CI 1.36 to 14.55) and pancreatic cancer (Nexposed = 3, RR = 3.70 95% CI 1.15 to 12.0). Use of any OC was also associated with non-significantly elevated risks of stomach cancer (Nexposed = 5, RR = 2.61, 95% CI 0.96 to 7.11), and colon cancer (Nexposed = 28, RR = 1.19, 95% CI 0.80 to 1.75).
Table 2

RR and CIsb for ever versus never use of OC insecticides, for all cancer sites±

 

N total

Any OCa

Chlordane

DDT

Lindane

Aldrin

Heptachlor

Toxaphene

Dieldrin

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

N exposed

RR

95% CI

All Cancer Sitesc

3,204

287

0.96

0.85–1.08

160

0.99

0.84–1.16

158

0.98

0.83–1.15

46

0.91

0.68–1.22

41

1.12

0.82–1.53

36

1.06

0.76–1.48

29

1.05

0.73–1.52

17

1.02

0.63–1.65

Solid tumors

  Bladder

103

4

0.64

0.23–1.77

1

_

_

3

0.83

0.26–2.67

1

_

_

0

_

_

0

_

_

1

_

_

0

_

_

  Colon

236

28

1.19

0.80–1.75

18

1.42

0.87–2.32

16

1.17

0.70–1.95

3

0.79

0.25–2.49

6

1.73

0.76–3.91

4

1.24

0.46–3.36

3

1.31

0.42–4.12

4

2.41

0.89–6.53

  Glioma

44

11

3.52

1.72–7.21

4

1.81

0.64–5.12

2

_

_

3

4.45

1.36–14.55

1

_

_

2

_

_

2

_

_

0

_

_

  Kidney

71

6

0.89

0.38–2.08

3

0.85

0.26–2.72

5

1.41

0.56–3.57

0

_

_

1

_

_

0

_

_

2

_

_

0

_

_

  Lung

203

15

0.70

0.41–1.20

10

0.90

0.47–1.71

10

0.84

0.44–1.59

2

_

_

2

_

_

1

_

_

5

2.13

0.87–5.21

2

_

_

  Melanoma (cutaneous)

145

12

1.08

0.59–1.97

4

0.63

0.23–1.72

5

0.88

0.36–2.18

2

_

_

3

2.20

0.69–7.02

3

2.40

0.75–7.64

1

_

_

1

_

_

  Pancreas

55

7

1.33

0.59–2.97

3

1.03

0.32–3.34

1

_

_

3

3.70

1.15–12.0

1

_

_

1

_

_

0

_

_

0

_

_

  Rectum

69

8

1.27

0.60–2.70

6

1.80

0.77–4.21

6

1.79

0.76–4.22

0

_

_

1

_

_

1

_

_

1

_

_

0

_

_

  Stomach

26

5

2.61

0.96–7.11

1

_

_

3

2.64

0.76–9.15

1

_

_

1

_

_

0

_

_

0

_

_

0

_

_

  Thyroid

54

5

0.66

0.26–1.63

4

0.97

0.36–2.67

1

_

_

0

_

_

1

_

_

1

_

_

0

_

_

0

_

_

Lymphohematopoietic malignancies

  NHL

233

28

1.23

0.82–1.83

17

1.35

0.82–2.22

17

1.35

0.81–2.22

6

1.60

0.71–3.60

1

_

_

3

1.03

0.33–3.24

3

1.49

0.48–4.68

0

_

_

  Multiple Myeloma

42

8

2.01

0.91–4.42

6

2.71

1.12–6.55

4

1.75

0.61–5.01

1

_

_

0

_

_

1

_

_

1

_

_

0

_

_

  Myeloid Leukemia

34

4

1.26

0.44–3.65

3

1.82

0.55–6.09

3

1.66

0.49–5.56

0

_

_

0

_

_

1

_

_

0

_

_

0

_

_

Female specific sites

  Breast

1,214

99

0.89

0.72–1.09

56

0.93

0.71–1.22

52

0.89

0.67–1.18

17

0.88

0.54–1.42

11

0.88

0.48–1.59

11

0.93

0.51–1.68

5

0.49

0.20–1.18

6

1.06

0.48–2.38

  ER + PR+

736

64

0.94

0.73–1.23

36

0.98

0.70–1.37

33

0.93

0.65–1.33

9

0.75

0.39–1.45

8

1.00

0.50–2.02

8

1.05

0.52–2.11

2

_

_

3

0.83

0.27–2.60

  ER-PR-

202

15

0.82

0.48–1.40

9

0.90

0.46–1.76

7

0.76

0.36–1.63

4

1.22

0.45–3.30

2

_

_

2

_

_

1

_

_

3

3.55

1.12–11.18

  ER + PR-

125

8

0.65

0.32–1.35

5

0.78

0.32–1.92

4

0.61

0.22–1.67

2

_

_

0

_

_

0

_

_

1

_

_

0

_

_

  Ovarian

106

9

0.65

0.30–1.61

7

1.05

0.40–2.89

5

0.77

0.20–2.46

2

_

_

2

_

_

2

_

_

1

_

_

1

_

_

  Uterine

276

20

0.83

0.50–1.32

10

0.80

0.40–1.50

10

0.82

0.42–1.56

2

_

_

4

1.50

0.60–4.06

3

1.12

0.40–3.51

2

_

_

1

_

_

Significant Findings are listed in boldface

AHS Agricultural Health Study, RR relative risks, OC organochlorines, ER estrogen receptor, PR progesterone receptor

± n ≥ 3 exposed cases

aEver use of any of the seven OC insecticides

bAdjusted for age, education, state of residence, pack-years smoked, and alcohol consumption

cInclusive of all reported cancer sites

Although chlordane use (Nexposed = 6, RR = 2.71, 95% CI 1.12 to 6.55) was significantly associated with an increased risk for MM, any OC use (Nexposed = 8, RR = 2.01, 95% CI 0.91 to 4.42) and DDT use (Nexposed = 4, RR = 1.75, 95% CI 0.61 to 5.01) were non-significantly associated with an increased risk of MM (Table 2). There were also several suggestive associations for lymphoematopoietic malignancies. Any OC use was non-significantly associated with an increased risk for NHL overall (Nexposed = 28, RR = 1.23, 95% CI 0.82 to 1.83). Similarly, use of chlordane (Nexposed = 17, RR = 1.30, 95% CI 0.82 to 2.22), DDT (Nexposed = 17, RR = 1.35, 95% CI 0.81 to 2.22), and lindane (Nexposed = 6, RR = 1.60, 95% CI 0.71 to 3.60) were also non-significantly associated with increased risks in NHL. We had limited power for NHL subtype analyses. However, all 28 OC exposed cases were B-cell lymphomas. Among women who reported any OC use, there were eight MM cases and six diffuse large B-cell lymphoma (DLBCL); no other B-cell subtype had more than four exposed cases.

We also evaluated hormone-mediated cancers including ovarian, uterine, and breast (see Table 2). No significant associations were found for any OC use or for use of the seven individual OCs and uterine or ovarian cancers. Similarly, we found no association between any OC use or for use of the seven individual OCs and breast cancer. In analyses of breast cancer subtype, there was a statistically significant elevated association between dieldrin use and ER-PR- breast cancer (Nexposed = 3, RR = 3.55, 95% CI 1.12 to 11.18).

Discussion

In this study, we prospectively evaluated associations between the reported personal use of individual OCs and incident cancers in a population of female farm spouses. Although the numbers of exposed cases were small, we observed statistically significant increased risks for use of individual OCs insecticides and several cancers, including any OC use and glioma, lindane use and glioma and pancreatic cancer, chlordane use and MM, and dieldrin use and ER−/PR- breast cancer.

In addition to chlordane, MM was non-significantly associated with any OC use and with DDT specifically. These associations are consistent with previous findings [1114, 17, 18]. The definition of NHL used in our study is based on the most recent lymphoma classification system, which includes MM as a subtype of NHL [50], whereas most previous studies relied on earlier classifications which considered MM separately. A previous population-based case–control study found non-significant positive associations of ever handling (mixing or applying) aldrin, DDT, or lindane with MM [51]. A pooled analysis of U.S. and Canadian case-controls studies found that DDT use was significantly associated with MM [17]; cumulative exposure to DDT, as measured by lifetime-days of use, was also significantly associated with an increasing risk trend for MM. Although not significant, in the current study, chlordane use was also positively associated with NHL and myeloid leukemia, DDT use was positively associated with NHL and myeloid leukemia, and lindane use was positively associated with NHL. There is evidence that some OCs, including lindane and DDT, cause oxidative stress and immunosuppressive effects, and that these mechanisms possibly play a role in the development of lymphohematopoietic cancers [7, 5255].

We observed no significant association with Any OC use and breast cancer overall. Although some studies have reported an increased risk of breast cancer among women exposed to OCs during critical developmental windows in early life [4143], our findings are consistent with most other studies that also did not evaluate timing of exposure [7, 29, 30, 3239]. Although we did not have information on timing of exposure, we conducted sensitivity analyses using year of birth as a surrogate for the potential for exposure during critical developmental periods. OCs were first registered in 1948, therefore we assumed women born before 1936 would not have any OC exposures prior to menarche. When we restricted analyses to women born after 1936, the RR for breast cancer and any OC use was 1.22 (0.94–1.59) (n = 61 exposed cases) compared to 0.84 (0.60–1.18) (n = 38 exposed cases) among women who were born prior to 1936. Although there was some evidence to indicate potential differences between the two groups, the test for interaction was not statistically significant (p = 0.11. An early study by Wolff et al. found a two- to four-fold increased risk of breast cancer among women with the highest serum DDE levels, with a positive trend with increasing serum DDE [30]. However, a follow-up study with a larger sample size found no evidence for an association of breast cancer risk with serum DDE levels [56]. Additional studies of breast cancer and OC exposures have examined associations with mirex, HCB, and chlordane; most of these studies also reflected null or inconclusive findings [33, 36, 5759].

We did, however, see an association between dieldrin use and ER−/PR- breast cancer based on only 3 exposed cases. Two previous studies reported positive associations with dieldrin use and breast cancer overall. The first, a Danish case–control study found a significant dose-related increased risk of breast cancer among women and increasing serum concentrations of dieldrin [34]. Additionally, a previous study of AHS farm spouses found evidence for a significant increased risk of breast cancer overall among women who never personally used dieldrin, but whose husbands’ did personally apply the pesticide [35]. This study was unable to assess associations between the wives’ personal use of dieldrin and breast cancer due to the low number of dieldrin exposed breast cancer cases. Our current analysis includes 60 more OC exposed cases and thirteen additional years of follow-up than this previous analysis [35], and was sufficiently powered to examine breast cancer subtypes. Few epidemiologic studies have examined associations between OC exposures and breast cancer subtypes [42, 6062], and most have not found positive associations with ER-negative breast cancers. In vitro and animal studies have suggested that dieldrin, DDT, endosulfan, HCH, and toxaphene have the potential to elicit tumor promoting effects mediated through the induction of ER, androgen receptor and aromatase activities [4648, 63, 64]. Given this body of literature and the small number of dieldrin exposed ER-PR- breast cancer cases, our positive finding warrants further investigation. Overall we do not see strong evidence of an association between use of an individual OC and breast cancer, consistent with the existing epidemiologic literature.

Aldrin use was associated with a non-statistically significant elevated risk for uterine cancer based on four exposed cases. Only one case–control study has examined OC exposures and endometrial cancer; no statistically significant associations were observed with several OC derivatives including DDE, oxychlordane, HCH, and HCB [44]. Very few occupational studies have examined the relationship between endometrial cancer and exposure to other OC compounds, including polychlorinated biphenyls (PCBs) [6567] and the majority of these studies’ findings were null. To our knowledge, this is the first prospective study to examine the relationship between personal use of specific OC insecticides and uterine cancer.

Any OC use and lindane specifically were associated with risk of glioma. While we lacked sufficient power for further subtype analyses, the OC-exposed glioma cases consisted of glioblastomas (n = 7), an astrocytoma (n = 1), an oligodendroma (n = 1), and mixed gliomas (n = 2). Previous studies of male farming populations have found some evidence for an increased risk of glioma with associated pesticide use [6872]. However, studies examining associations between glioma and pesticide exposures among women, in agricultural populations, have provided inconsistent results. In an earlier case–control study of central nervous system cancers among women across twenty-four U.S. states, increased risks were found for women generally exposed to herbicides, insecticides, or fungicides [73]. An analysis of occupational risk factors for glioma found significantly increased risks among women involved in occupations in agricultural services and farming, though this analysis did not examine exposures to specific pesticides [74]. However, a case–control analysis of women in Nebraska found no association between individually evaluated OCs (i.e. aldrin, chlordane, DDT, dieldrin, heptachlor and lindane) and brain cancer [68]. Similarly, in a case–control analysis of women in the Midwest, no association was found for gliomas and the personal application of pesticides including OCs [75]. Mechanisms of action for OC-induced gliomas have not been proposed; however, in vitro studies have found that neurotoxic effects induced by the interaction of OCs with ER-mediated signaling pathways may play a role [76].

The increased risk of pancreatic cancer associated with lindane use in our study was based on only three exposed cases. Some studies have shown significant increased risks for pancreatic cancer with occupational DDT exposure [26, 27] and significantly higher levels of DDT exposure among pancreatic cancer cases versus controls [27]. However, a previous AHS study found no evidence for an increased risk of pancreatic cancer with the OCs aldrin, DDT, heptachlor or toxaphene [77]. The aforementioned study did not evaluate risk estimates among the spouses only, but examined combined risk estimates among the applicators and their spouses. Furthermore, a lack of exposed cases prohibited the insecticide-specific evaluation of chlordane, dieldrin and lindane. To our knowledge, no other studies have evaluated OC use and pancreatic cancers among women.

Strengths of our study include the prospective longitudinal design with little loss-to-follow-up, questionnaire information on the use of specific OCs, and regular assessment of cancer incidence and mortality via linkage with state registries. The AHS also has detailed information on many possible confounders. Most previous studies of OC exposures and cancer, except for studies of DDT and breast cancer [7, 2932, 36, 38, 78] have primarily focused on occupationally-exposed men [79]. Our study examined the personal use of DDT, and other specific OCs, in a population of farm women. Few studies have evaluated personal use of specific OCs. While breast cancer has been the most widely studied cancer with respect to OCs, in particular DDT, no studies thus far have prospectively studied OCs and other hormone-mediated cancers.

Limitations of this analysis include the small number of cases exposed to specific OCs and lack of information on duration, time period, and intensity of OC use. While we had a low response rate of the female and family health questionnaire, our reported results and final models were based solely on information collected from the spousal enrollment questionnaire. Questionnaire information was collected at study enrollment (1993–1997), thus changes in individual characteristics (i.e. menopausal status, smoking) since enrollment were not captured in this analysis. In addition, most OCs examined in this analysis have been banned for use in the United States since the 1970s. Because OCs have long half-lives, and are known to persist in the environment and human body for long periods of time [13], exposure to OCs through environmental exposure pathways may also contribute to lifetime cumulative exposure. This could be particularly important in farm situations where OCs may have been used in the past.

Conclusions

We observed significant increased risks for some cancers associated with individual OC insecticides. Despite the large size of the cohort, the numbers of exposed women and cancer cases were small for most cancer sites of interest. While some of our findings are consistent with previous findings, results need replication with longer follow-up time in other studies. Due to the environmental persistence of OCs, future research should attempt to expand on these findings by assessing environmental sources of OC exposures in order to fully evaluate the role of OC exposures on cancer risk in women.

Abbreviations

AHS: 

Agricultural health study

CI: 

Confidence interval

DDT: 

Dichlorodiphenyltrichloroethane

DLBCL: 

Diffuse large B-cell lymphoma

HCB: 

Hexachlorobenzene

HCH: 

Hexachlorocyclohexane

IARC: 

International Agency for Research on Cancer

MM: 

Multiple myeloma

NHL: 

Non-Hodgkin lymphoma

OCs: 

Organochlorines

PCBs: 

Polychlorinated biphenyls

PCP: 

Pentachlorophenol

RR: 

Relative risks

SEER: 

Surveillance, epidemiology, and end results

TCP: 

2,4,6-trichlorophenol

DDE: 

Dichlorodiphenyldichloroethylene

Declarations

Acknowledgements

Data in this analysis are based on the AHS data release P1REL201209.00.

Funding

This work was supported by the intramural research program of the NIH, the National Cancer Institute (Z01-CP010119) and the National Institute of Environmental Health Sciences (Z01-ES049030) and by the NIEHS sponsored Center Grant P30 ES005022.

Availability of data and materials

The data sets used and/or analyzed during the current study may be made available through approval by the Agricultural Health Study executive committee.

Authors’ contributions

LML led the statistical analyses and wrote the first draft of the manuscript. CCL provided input on the statistical analyses and manuscript revisions. MCF provided guidance on manuscript revisions. GA participated in manuscript preparation and statistical analyses. AB, DPS, MGR and SK participated in the manuscript preparation. MGR participated in the manuscript preparation. LBF provided guidance in study design, statistical analyses, and manuscript revisions. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Study procedures and documents were approved in 1993 by the National Cancer Institute Special Studies Institutional Review Board, Westat Institutional Review Board, and the University of Iowa Institutional Review Board-01.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health
(2)
School of Public Health, Rutgers University
(3)
Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health
(4)
School of Environmental and Biological Sciences, Rutgers University

References

  1. Persistent Organic Pollutants: A Global Issue, A Global Response. 2009. Available from: http://www2.epa.gov/international-cooperation/persistent-organic-pollutants-global-issue-global-response. Accessed 18 Aug 2017.
  2. U.S. Environmental Protection Agency. DDT: a review of scientific and economic aspects on the decision to ban its use as a pesticide. U.S. EPA: Washington D.C.; 1975.Google Scholar
  3. Gorman S, Tynan E. Persistent organic pollutants-a legacy of environmental harm and threats to health. Environ Strategy Notes. 2003;6:1–4.Google Scholar
  4. Draft PBT National Action Plan for the Level 1 Pesticides, The U.S. EPA Persistent Bioaccumulative and Toxic Pollutants (PBT) Pesticides Work Group, Editor. 2000, U.S. Environmental Protection Agency.Google Scholar
  5. U.S. Environmental Protection Agency. Pesticide News Story: Remaining Lindane Registrations Cancelled. U.S. EPA; 2006.Google Scholar
  6. U.S. Environmental Protection Agency. Endosulfan Phase-out; 2010. Available from: https://archive.epa.gov/pesticides/reregistration/web/html/endosulfan-agreement.html#agreement. Accessed 26 May 2017.
  7. Loomis D, Guyton K, Grosse Y, El Ghissasi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Mattock H, Straif K. Carcinogenicity of lindane, DDT, and 2,4-dichlorophenoxyacetic acid. Lancet Oncol. 2015;16(8):891–2.View ArticleGoogle Scholar
  8. Guyton K, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Mattock H, Straif K. Carcinogenicity of pentachlorophenol and some related compounds. Lancet Oncol. 2016;17:1637–38.Google Scholar
  9. International Agency for Research on Cancer, World Health Organization. Some thyrotropic agents, in Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol. 79. Lyon: WHO; 2001.Google Scholar
  10. International Agency for Research on Cancer, World Health Organization. Overall evaluations of carcinogenicity: an updating of IARC monographs, in Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon: WHO. 1987;1–42(7).Google Scholar
  11. McDuffie HH, Pahwa P, McLaughlin JR, et al. Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health. Cancer Epidemiol Biomarkers Prev. 2001;10:115–63.Google Scholar
  12. Alavanja MC, et al. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the agricultural health study. PLoS One. 2014;9(10):e109332.View ArticleGoogle Scholar
  13. Spinelli JJ, Ng CH, Weber JP, et al. Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer. 2007;121:2767–75.View ArticleGoogle Scholar
  14. Eriksson M, Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case–control study. Br J Ind Med. 1992;49:95–103.Google Scholar
  15. Pahwa M, et al. Pesticide use, immunologic conditions, and risk of non-Hodgkin lymphoma in Canadian men in six provinces. Int J Cancer. 2012;131(11):2650–9.View ArticleGoogle Scholar
  16. De Roos AJ, et al. Integrative assessment of multiple pesticides as risk factors for non-Hodgkin's lymphoma among men. Occup Environ Med. 2003;60(9):E11.View ArticleGoogle Scholar
  17. Presutti R, et al. Pesticide exposures and the risk of multiple myeloma in men: an analysis of the north American pooled project. Int J Cancer. 2016;139(8):1703–14.View ArticleGoogle Scholar
  18. Cocco P, et al. Cancer mortality among men occupationally exposed to dichlorodiphenyltrichloroethane. Cancer Res. 2005;65(20):9588–94.View ArticleGoogle Scholar
  19. Orsi L, et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case–control study. Occup Environ Med. 2009;66(5):291–8.View ArticleGoogle Scholar
  20. Purdue MP, et al. Occupational exposure to organochlorine insecticides and cancer incidence in the agricultural health study. Int J Cancer. 2007;120(3):642–9.View ArticleGoogle Scholar
  21. Persson EC, Graubard BI, Evans AA, et al. Dichlorodiphenyltrichloroethane and risk of hepatocellular carcinoma. Int J Cancer. 2012;131:2078–84.View ArticleGoogle Scholar
  22. Zhao B, Shen H, Liu F, Sheng L, Jianjun N, Fei G, Xueli S. Exposure to organochlorine pesticides is an independent risk factor of hepatocellular carcinoma: a case–control study. J Expo Sci Environ Epidemiol. 2012;22:541–8.View ArticleGoogle Scholar
  23. McGlynn KA, Abnet CC, Zhang M, et al. Serum concentrations of 1,1,1-trichloro-2,2-bis(pchlorophenyl)ethane (DDT) and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and risk of primary liver cancer. J Natl Cancer Inst. 2006;98:1005–10.View ArticleGoogle Scholar
  24. McGlynn KA, Quraishi SM, Graubard BI, Weber JP, Rubertone MV, Erickson RL. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J Natl Cancer Inst Monogr. 2008;100(9):663–71.View ArticleGoogle Scholar
  25. Koutros S, et al. Risk of total and aggressive prostate cancer and pesticide use in the agricultural health study. Am J Epidemiol. 2013;177(1):59–74.View ArticleGoogle Scholar
  26. Garabrant DH, et al. DDT and related compounds and risk of pancreatic cancer. J Natl Cancer Inst. 1992;84(10):764–71.View ArticleGoogle Scholar
  27. Hoppin JA, et al. Pancreatic cancer and serum organochlorine levels. Cancer Epidemiol Biomark Prev. 2000;9(2):199–205.Google Scholar
  28. Ruder AM, et al. Gliomas and farm pesticide exposure in men: the upper midwest health study. Arch Environ Health. 2004;59(12):650–7.View ArticleGoogle Scholar
  29. Calle EE, et al. Organochlorines and breast cancer risk. CA Cancer J Clin. 2002;52(5):301–9.View ArticleGoogle Scholar
  30. Wolff MS, et al. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst. 1993;85(8):648–52.View ArticleGoogle Scholar
  31. Wolff MS, et al. Organochlorine exposures and breast cancer risk in new York City women. Environ Res. 2000;84(2):151–61.View ArticleGoogle Scholar
  32. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin. Environ Health Perspect. 2001;109(Suppl 1):35–47.View ArticleGoogle Scholar
  33. Itoh H, et al. Serum organochlorines and breast cancer risk in Japanese women: a case–control study. Cancer Causes Control. 2009;20(5):567–80.View ArticleGoogle Scholar
  34. Hoyer AP, et al. Organochlorine exposure and risk of breast cancer. Lancet. 1998;352(9143):1816–20.View ArticleGoogle Scholar
  35. Engel LS, et al. Pesticide use and breast cancer risk among farmers' wives in the agricultural health study. Am J Epidemiol. 2005;161(2):121–35.View ArticleGoogle Scholar
  36. Ahlborg UG, et al. Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Crit Rev Toxicol. 1995;25(6):463–531.View ArticleGoogle Scholar
  37. Gatto NM, et al. Serum organochlorines and breast cancer: a case–control study among African-American women. Cancer Causes Control. 2007;18(1):29–39.View ArticleGoogle Scholar
  38. Salehi F, et al. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors. J Toxicol Environ Health B Crit Rev. 2008;11(3–4):276–300.View ArticleGoogle Scholar
  39. Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect. 1997;105(Suppl 4):891–6.View ArticleGoogle Scholar
  40. Cohn BA, et al. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect. 2007;115(10):1406–14.Google Scholar
  41. Cohn BA. Developmental and environmental origins of breast cancer: DDT as a case study. Reprod Toxicol. 2011;31(3):302–11.View ArticleGoogle Scholar
  42. Niehoff NM, et al. Childhood and adolescent pesticide exposure and breast cancer risk. Epidemiology. 2016;27(3):326–33.View ArticleGoogle Scholar
  43. White AJ, et al. Exposure to fogger trucks and breast cancer incidence in the Long Island breast cancer study project: a case–control study. Environ Health. 2013;12:24.View ArticleGoogle Scholar
  44. Weiderpass E, et al. Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2000;9(5):487–93.Google Scholar
  45. Mrema EJ, et al. Persistent organochlorinated pesticides and mechanisms of their toxicity. Toxicology. 2013;307:74–88.View ArticleGoogle Scholar
  46. Silva E, Kabil A, Kortenkamp A. Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010;245(2):160–70.View ArticleGoogle Scholar
  47. Soto AM, Chung KL, Sonnenschein C. The pesticides endosulfan, toxaphene, and dieldrin have estrogenic effects on human estrogen-sensitive cells. Environ Health Perspect. 1994;102(4):380–3.View ArticleGoogle Scholar
  48. Soto AM, et al. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect. 1995;103(Suppl 7):113–22.View ArticleGoogle Scholar
  49. Alavanja MC, Sandler DP, McMaster SB, Zahm SH, McDonnell CJ, Lynch CF, Pennybacker M, Rothman N, Dosemeci M, Bond AE, Blair A. The agricultural health study. Environ Health Perspect. 1996;104:362–9.View ArticleGoogle Scholar
  50. SEER Program, N.C.I., Lymphoma Subtype Recodes. Accessed: August 18, 2016.Google Scholar
  51. Brown LM, et al. Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes Control. 1993;4(2):153–6.View ArticleGoogle Scholar
  52. Hong HL, Boorman GA. Residual myelotoxicity of lindane in mice. Fundam Appl Toxicol. 1993;21(4):500–7.View ArticleGoogle Scholar
  53. Daniel V, et al. Associations of dichlorodiphenyltrichloroethane (DDT) 4.4 and dichlorodiphenyldichloroethylene (DDE) 4.4 blood levels with plasma IL-4. Arch Environ Health. 2002;57(6):541–7.View ArticleGoogle Scholar
  54. Reed A, et al. Immunomodulation of human natural killer cell cytotoxic function by organochlorine pesticides. Hum Exp Toxicol. 2004;23(10):463–71.View ArticleGoogle Scholar
  55. Thomas PT. Pesticide-induced immunotoxicity: are Great Lakes residents at risk? Environ Health Perspect. 1995;103(Suppl 9):55–61.View ArticleGoogle Scholar
  56. Wolff MS, et al. Risk of breast cancer and organochlorine exposure. Cancer Epidemiol Biomark Prev. 2000;9(3):271–7.Google Scholar
  57. Pavuk M, et al. Case–control study of PCBs, other organochlorines and breast cancer in eastern Slovakia. J Expo Anal Environ Epidemiol. 2003;13(4):267–75.View ArticleGoogle Scholar
  58. Zheng T, et al. Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. Cancer Epidemiol Biomark Prev. 1999;8(5):407–11.Google Scholar
  59. Zheng T, et al. Oxychlordane and trans-nonachlor in breast adipose tissue and risk of female breast cancer. J Epidemiol Biostat. 2000;5(3):153–60.Google Scholar
  60. Dewailly E, et al. High organochlorine body burden in women with estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1994;86(3):232–4.View ArticleGoogle Scholar
  61. Woolcott CG, et al. Organochlorines and breast cancer risk by receptor status, tumor size, and grade (Canada). Cancer Causes Control. 2001;12(5):395–404.View ArticleGoogle Scholar
  62. Hoyer AP, et al. Organochlorine exposures influence on breast cancer risk and survival according to estrogen receptor status: a Danish cohort-nested case–control study. BMC Cancer. 2001;1:8.View ArticleGoogle Scholar
  63. Andersen HR, et al. Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol Appl Pharmacol. 2002;179(1):1–12.View ArticleGoogle Scholar
  64. Kelce WR, et al. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature. 1995;375(6532):581–5.View ArticleGoogle Scholar
  65. Lynge E. A follow-up study of cancer incidence among workers in manufacture of phenoxy herbicides in Denmark. Br J Cancer. 1985;52(2):259–70.View ArticleGoogle Scholar
  66. Brown DP. Mortality of workers exposed to polychlorinated biphenyls--an update. Arch Environ Health. 1987;42(6):333–9.View ArticleGoogle Scholar
  67. Kogevinas M, et al. Soft tissue sarcoma and non-Hodgkin's lymphoma in workers exposed to phenoxy herbicides, chlorophenols, and dioxins: two nested case–control studies. Epidemiology. 1995;6(4):396–402.View ArticleGoogle Scholar
  68. Lee W, Colt JS, Heineman EF, McComb R, Weisenburger DD, Lijinsky W, Ward MH. Agricultural pesticide use and risk of glioma in Nebraska, United States. Occup Environ Med. 2005;62:786–92.View ArticleGoogle Scholar
  69. Bohnen NI, Kurland LT. Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. J Neurol Sci. 1995;132(2):110–21.View ArticleGoogle Scholar
  70. Dean G. Deaths from primary brain cancers, lymphatic and haematopoietic cancers in agricultural workers in the Republic of Ireland. J Epidemiol Community Health. 1994;48(4):364–8.View ArticleGoogle Scholar
  71. Brownson RC, et al. An analysis of occupational risks for brain cancer. Am J Public Health. 1990;80(2):169–72.View ArticleGoogle Scholar
  72. Musicco M, et al. Gliomas and occupational exposure to carcinogens: case–control study. Am J Epidemiol. 1982;116(5):782–90.View ArticleGoogle Scholar
  73. Cocco P, Heineman EF, Dosemeci M. Occupational risk factors for cancer of the central nervous system (CNS) among US women. Am J Ind Med. 1999;36(1):70–4.View ArticleGoogle Scholar
  74. Zheng T, et al. Occupational risk factors for brain cancer: a population-based case–control study in Iowa. J Occup Environ Med. 2001;43(4):317–24.View ArticleGoogle Scholar
  75. Carreon T, et al. Gliomas and farm pesticide exposure in women: the upper Midwest health study. Environ Health Perspect. 2005;113(5):546–51.View ArticleGoogle Scholar
  76. Briz V, et al. Differential estrogenic effects of the persistent organochlorine pesticides dieldrin, endosulfan, and lindane in primary neuronal cultures. Toxicol Sci. 2011;120(2):413–27.View ArticleGoogle Scholar
  77. Andreotti G, et al. Agricultural pesticide use and pancreatic cancer risk in the agricultural health study cohort. Int J Cancer. 2009;124(10):2495–500.View ArticleGoogle Scholar
  78. Lopez-Cervantes M, et al. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect. 2004;112(2):207–14.View ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement